**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings. The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$764,569 Vol.
Mar 31, 2026
June 30
2%
December 31
27%
$764,569 Vol.
June 30
$340,710 Vol.
2%
December 31
$158,977 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings.
The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Volume
$764,569End Date
Mar 31, 2026Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings.
The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$764,569End Date
Mar 31, 2026Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of state-licensed medical marijuana and FDA-approved cannabis products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** This step addressed research access and certain state programs but left broader federal reclassification of all marijuana from Schedule I pending further administrative proceedings. The DEA withdrew prior hearing plans and scheduled a new expedited evidentiary hearing to begin June 29, 2026, focused on moving the substance as a whole to Schedule III. Trader sentiment on timing markets reflects the accelerated timeline enabled by the executive order, tempered by uncertainty over hearing outcomes, potential litigation, public comment periods, and the precise effective date of any final rule. Historical precedent shows administrative rescheduling can encounter delays even after proposed rules and agency directives, while the current process includes firm procedural deadlines aimed at faster completion. Key variables for near-term resolution include hearing testimony, any resulting proposed or final rulemaking, and court challenges that could extend timelines beyond 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions